Literature DB >> 8737144

Effect of pentoxifylline on the course of systemic Candida albicans infection in mice.

A Louie1, A L Baltch, M A Franke, W J Ritz, R P Smith, J K Singh, M A Gordon.   

Abstract

Pentoxifylline can decrease the production of tumour necrosis factor alpha (TNF alpha) by endotoxin-stimulated macrophages and may improve survival in animals with overwhelming bacterial sepsis. In this study various doses of pentoxifylline were administered to mice with systemic Candida albicans infection to determine its effect on serum TNF alpha levels, organ fungal burden, and host survival. Intraperitoneal injections of pentoxifylline at 20 mg/kg every 8 h did not affect these endpoints. However, fungal counts were significantly higher in kidneys of animals that received 30 and 60 mg/kg of pentoxifylline every 8 h when compared to controls. Injection of 60 mg/kg of pentoxifylline at 8 h intervals also significantly shortened mean survival from 5.8 to 3.8 days (P = 0.01). Pentoxifylline did not affect peripheral WBC counts, serum TNF alpha and interleukin-6 levels, or the density of neutrophils in tissues. In vitro, pentoxifylline decreased the production of TNF alpha by C. albicans-stimulated macrophages in a dose-dependent manner, but only at concentrations greater than 100 mg/L. In contrast, pentoxifylline suppressed TNF alpha production by endotoxin-stimulated macrophages at concentrations as low as 10 mg/L. Thus, higher doses of pentoxifylline are detrimental in systemic C. albicans infection. However, the detrimental effect is not mediated by alterations in serum TNF alpha or interleukin-6 levels or the aggregation of neutrophils in tissues.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8737144     DOI: 10.1093/jac/37.5.943

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  5 in total

1.  Pentoxifylline does not improve outcome in a murine model for the multiple-organ dysfunction syndrome.

Authors:  T J H Volman; R J A Goris; T Hendriks
Journal:  Intensive Care Med       Date:  2005-02-15       Impact factor: 17.440

2.  Pharmacokinetics of pentoxifylline and its metabolites in healthy mice and in mice infected with Candida albicans.

Authors:  K Miller; A Louie; A L Baltch; R P Smith; P J Davis; M A Gordon
Journal:  Antimicrob Agents Chemother       Date:  1998-09       Impact factor: 5.191

3.  Pentoxifylline immunomodulation in the treatment of experimental chronic pulmonary paracoccidioidomycosis.

Authors:  Damaris Elena Lopera; Tonny Williams Naranjo; José Miguel Hidalgo; Laura Echeverri; Jairo Hernando Patiño; Ángela Restrepo Moreno; Henrique Leonel Lenzi; Luz Elena Cano
Journal:  Fibrogenesis Tissue Repair       Date:  2015-06-01

4.  A Neonatal Murine Escherichia coli Sepsis Model Demonstrates That Adjunctive Pentoxifylline Enhances the Ratio of Anti- vs. Pro-inflammatory Cytokines in Blood and Organ Tissues.

Authors:  Esther M Speer; Elizabet Diago-Navarro; Lukasz S Ozog; Mahnoor Raheel; Ofer Levy; Bettina C Fries
Journal:  Front Immunol       Date:  2020-09-23       Impact factor: 7.561

5.  Pentoxifylline Alone or in Combination with Gentamicin or Vancomycin Inhibits Live Microbe-Induced Proinflammatory Cytokine Production in Human Cord Blood and Cord Blood Monocytes In Vitro.

Authors:  Esther M Speer; Elizabeth Diago-Navarro; Lukasz S Ozog; David J Dowling; Wei Hou; Mahnoor Raheel; Bettina C Fries; Ofer Levy
Journal:  Antimicrob Agents Chemother       Date:  2018-11-26       Impact factor: 5.191

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.